Loading clinical trials...
Loading clinical trials...
A 4-part Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of M254 in Healthy Volunteers and in Patients With Immune Thrombocytopenic Purpura
Conditions
Interventions
Biological: M254
Placebo
+1 more
Locations
28
United States
University of Southern California
Los Angeles, California, United States
Oncology Institute of Hope and Innovation
Whittier, California, United States
Lakes Research
Miami Lakes, Florida, United States
University of South Florida
St. Petersburg, Florida, United States
Duke University Medical Center
Durham, North Carolina, United States
Taussig Cancer Insititute Cleveland Clinic
Cleveland, Ohio, United States
Start Date
December 21, 2018
Primary Completion Date
June 9, 2021
Completion Date
June 9, 2021
Last Updated
May 28, 2025
NCT06722235
NCT00162006
NCT02877212
Lead Sponsor
Momenta Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions